Clinical trial
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating…
NCT00110019 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00110019 |
|---|---|
| Title | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| Official title | A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma |
| Intervention type | Drug, Other |
| Interventions | Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Placebo, Sorafenib Tosylate |
| Enrollment | 823 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Aug 1, 2012 |
| First posted | May 4, 2005 |
| Last update posted | Oct 19, 2015 |
| Countries | Australia, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: